Get the support you need tounderstand and treat an MH crisis
When an MH crisis occurs, you and your staff need to act quickly.2 Our tools and resources provide you with insights on MH disease education and RYANODEX® (dantrolene sodium) for injectable suspension product information that help you take action when you need to.
RYANODEX® educational tools and support
Dosing and Administration Guide
Step-by-step instructions on how to administer RYANODEX®, including a dosage schedule based on patient’s weight.
Reconstitution and Administration Video
See how to quickly and easily reconstitute and administer RYANODEX®.
MH Insights Video
Henry Rosenberg, MD, President of MHAUS, provides insight on the importance of timely treatment during an MH crisis.
MH Risk Infographic
Read about MH preparation from a broader perspective.
P&T Committee Support Kit
Clinical information on RYANODEX® and MH treatment with dantrolene sodium.
- White Paper: Innovative Option for the Treatment of Malignant Hyperthermia (MH)
- RYANODEX® Fact Sheet
- Prescribing Information
- FDA Approval Letter
Malignant hyperthermia data can be found in Anesthesia & Analgesia.
- Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg. 2010;110(2):498-507.
- Riazi S, Larach MG, Hu C, Wijeysundera D, Massey C, Kraeva N. Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands. Anesth Analg. 2014;118(2):381-387.
RYANODEX® is designed for speed and efficiency in an MH crisis1,7
Every minute counts to reverse the potentially fatal effects of MH.2,3
See how RYANODEX® allows for rapid reconstitution within 10 seconds so that administration of dantrolene sodium can occur in less than 1 minute, with 1 vial, by 1 provider.1